Filing Details
- Accession Number:
- 0001179110-22-000334
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2022-01-07 16:27:15
- Reporting Period:
- 2022-01-05
- Accepted Time:
- 2022-01-07 16:27:15
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
815094 | Abiomed Inc | ABMD | Surgical & Medical Instruments & Apparatus (3841) | 042743260 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1638242 | A Todd Trapp | C/O Abiomed, Inc., 22 Cherry Hill Dr Danvers MA 01923 | Vice President, Cfo | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock, $0.01 Par Value | Disposition | 2022-01-05 | 1,000 | $359.43 | 14,063 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | S | Direct |
Reported Derivative Holdings
Sec. Name | Sec. Type | Price | Date | Expiration Date | Amount | Remaning Holdings | Nature of Ownership |
---|---|---|---|---|---|---|---|
Common Stock | Stock Option (Right to Buy) | $266.39 | 2020-05-30 | 2029-05-30 | 0 | 7,000 | Direct |
Common Stock | Stock Option (right to buy) | $223.90 | 2021-05-29 | 2030-05-29 | 0 | 6,530 | Direct |
Common Stock | Stock Option (right to buy) | $283.88 | 2022-05-25 | 2031-05-25 | 0 | 3,737 | Direct |
Expiration Date | Amount | Remaning Holdings | Nature of Ownership |
---|---|---|---|
2029-05-30 | 0 | 7,000 | Direct |
2030-05-29 | 0 | 6,530 | Direct |
2031-05-25 | 0 | 3,737 | Direct |
Footnotes
- Sale of common stock pursuant to reporting owner's 10b5-1 plan.
- Grant to reporting person of option to buy the number of shares of Common Stock set forth in Table II, Column 7, under the ABIOMED, Inc. 2015 Omnibus Incentive Plan.
- These options become exercisable in annual 33-1/3% increments, commencing on the date shown in Table II, Column 6.
- This price represents the sale price of the transactions on the reported date at $359.43. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer.